Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-26 4:15 pm Purchase | 2024-11-22 | 13D | Verrica Pharmaceuticals Inc. VRCA | Manning Paul B | 52,504,049 49.900% | 37,114,568 (+241.17%) | Filing History |
| 2024-11-12 5:35 pm Purchase | 2024-09-30 | 13G | Liquidia Corporation LQDA | Manning Paul B | 6,679,132 7.900% | 350,411 (+5.54%) | Filing History |
| 2024-02-14 4:18 pm Purchase | 2023-12-31 | 13G | Liquidia Corporation LQDA | Manning Paul B | 6,328,721 9.200% | 304,608 (+5.06%) | Filing History |
| 2023-08-21 4:01 pm Purchase | 2023-08-16 | 13D | Taysha Gene Therapies, Inc. TSHA | Manning Paul B | 23,476,333 12.600% | 16,486,472 (+235.86%) | Filing History |
| 2023-02-14 6:28 pm Unchanged | 2022-10-22 | 13G | Pasithea Therapeutics Corp. KTTA | Manning Paul B | 170,435 11.300% | 0 (Unchanged) | Filing History |
| 2023-02-14 4:24 pm Sale | 2022-12-31 | 13G | Acumen Pharmaceuticals, Inc. ABOS | Manning Paul B | 3,205,128 7.800% | -805,550 (-20.09%) | Filing History |
| 2023-02-14 4:06 pm Purchase | 2022-12-31 | 13G | Liquidia Corporation LQDA | Manning Paul B | 6,024,113 9.300% | 848,941 (+16.40%) | Filing History |
| 2022-11-02 4:02 pm Purchase | 2022-10-31 | 13D | Taysha Gene Therapies, Inc. TSHA | Manning Paul B | 6,989,861 11.200% | 1,694,554 (+32.00%) | Filing History |
| 2022-07-15 4:15 pm Purchase | 2022-07-05 | 13D | Verrica Pharmaceuticals Inc. VRCA | Manning Paul B | 15,389,481 37.400% | 4,761,904 (+44.81%) | Filing History |
| 2022-06-29 4:30 pm Purchase | 2022-06-22 | 13G | Pasithea Therapeutics Corp. KTTA | Manning Paul B | 170,435 9.800% | 170,435 (New Position) | Filing History |
| 2022-02-14 7:27 pm Purchase | 2021-12-31 | 13G | Acumen Pharmaceuticals, Inc. ABOS | Manning Paul B | 4,010,678 9.900% | 4,010,678 (New Position) | Filing History |
| 2022-02-14 4:38 pm Purchase | 2021-07-29 | 13D | Candel Therapeutics, Inc. CADL | Manning Paul B | 4,073,316 13.600% | 4,073,316 (New Position) | Filing History |
| 2022-02-14 4:37 pm Purchase | 2021-12-31 | 13G | Verrica Pharmaceuticals Inc. VRCA | Manning Paul B | 10,627,577 38.600% | 789,830 (+8.03%) | Filing History |
| 2022-02-14 4:31 pm Purchase | 2021-12-31 | 13G | Liquidia Corporation LQDA | Manning Paul B | 5,175,172 10.000% | 233,131 (+4.72%) | Filing History |
| 2021-02-16 4:04 pm Purchase | 2020-12-31 | 13G | Verrica Pharmaceuticals Inc. VRCA | Manning Paul B | 9,837,747 38.000% | 194,500 (+2.02%) | Filing History |
| 2021-02-16 4:04 pm Purchase | 2020-12-31 | 13G | Liquidia Corporation LQDA | Manning Paul B | 4,942,041 11.400% | 4,942,041 (New Position) | Filing History |
| 2020-10-05 5:26 pm Purchase | 2020-09-23 | 13D | Taysha Gene Therapies, Inc. TSHA | Manning Paul B | 5,295,307 14.300% | 5,295,307 (New Position) | Filing History |